MedTrace Logo

Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)

NCT01440062 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-07-29

No results posted yet for this study

Summary

Examination of efficacy, safety and tolerability of vitamin D3 in the treatment of Multiple Sclerosis (MS).

Conditions

Interventions

DRUG

Verum arm receiving Vitamin D oil

oil: 20000 IU/g tablet: 400 IU/g every second day

DRUG

low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day

neutral oil and a low dose of vitamin D

Sponsors & Collaborators

  • NeuroCure Clinical Research Center, Charite, Berlin

    collaborator OTHER

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Jan-Markus Dörr, Dr. · Charite

  • Jan-Markus Dörr, Dr. · Charite-NeuroCure

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01440062 on ClinicalTrials.gov